Astellas and Vir Strike Global Deal to Advance VIR-5500 for Prostate Cancer
Astellas and Vir Biotechnology announced a global strategic collaboration to co-develop and co-commercialize VIR-5500, a PSMA-targeting PRO-XTEN dual-masked T-cell engager for prostate cancer; U.S. commercialization led by Astellas (Vir may co-promote), ex-U.S. commercialization to Astellas, development costs shared 60/40 (Astellas/Vir), Vir to receive $335 million upfront/near-term payments and up to $1.37 billion in milestones, with royalties on ex-U.S. net sales and a potential 50/50 U.S. profit/loss share if Vir elects to co-promote; closing subject to customary regulatory clearances.
